PFM Health Sciences, LP
13F Reported Value
ⓘ$1.2B
incl. option notional
Equity Holdings
ⓘ$1.2B
Option Notional
ⓘ$13.6M
$5.7M puts / $8.0M calls
Holdings
98
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
PFM Health Sciences, LP disclosed 98 positions worth $1.2B in its Form 13F-HR for Q2 2026 — $1.2B in common stock plus $13.6M of put/call option positions (reported at underlying notional value, not premium at risk), led by $ASND (Ascendis Pharma A/S) at 5.4% of the equity portfolio, followed by $AXSM and $LLY. During the quarter the fund opened 34 new positions and exited 18 — including a new stake in $HUM. The portfolio is most concentrated in Healthcare (93.5% of disclosed assets). All figures are sourced directly from PFM Health Sciences, LP’s Form 13F-HR filing with the SEC under CIK 1442756.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 44.8#1,898
Quality
$62.2M233,171 sh - 40.8#2,087
Quality
$53.8M219,596 sh - 87.5#2
Quality
$47.1M39,258 sh - —
Quality
$38.7M160,768 sh - 58.9
Quality
$37.5M94,375 sh - 62.7
Quality
$36.7M88,276 sh - 76.5
Quality
$36.0M213,407 sh - 30.0
Quality
$29.2M308,385 sh - 71.3
Quality
$27.1M49,991 sh - —
Quality
$26.8M143,222 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Ascendis Pharma A/S$ASND | 44.8#1,898 | $62.2M | 233,171 |
 Axsome Therapeutics, Inc.$AXSM | 40.8#2,087 | $53.8M | 219,596 |
 ELI LILLY & Co$LLY | 87.5#2 | $47.1M | 39,258 |
 Jazz Pharmaceuticals plc$JAZZ | — | $38.7M | 160,768 |
 HUMANA INC$HUM | 58.9 | $37.5M | 94,375 |
 UNITEDHEALTH GROUP INC$UNH | 62.7 | $36.7M | 88,276 |
 NEUROCRINE BIOSCIENCES INC$NBIX | 76.5 | $36.0M | 213,407 |
 Inhibrx Biosciences, Inc.$INBX | 30.0 | $29.2M | 308,385 |
 UNITED THERAPEUTICS Corp$UTHR | 71.3 | $27.1M | 49,991 |
 Revolution Medicines, Inc.$RVMD | — | $26.8M | 143,222 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of PFM Health Sciences, LP's 98 positions.
Showing top 10 of 98 holdings.
Sector Allocation
Healthcare
$1.1B
Technology
$73.0M
Consumer Staples
$2.1M
Full Holdings — PFM Health Sciences, LP (Q2 2026)
All 98 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $ASND | Ascendis Pharma A/S | $62.2M | 5.4% | -98% | 44.8 |
| 2 | $AXSM | Axsome Therapeutics, Inc. | $53.8M | 4.7% | -17% | 40.8 |
| 3 | $LLY | ELI LILLY & Co | $47.1M | 4.1% | -40% | 87.5 |
| 4 | $JAZZ | Jazz Pharmaceuticals plc | $38.7M | 3.4% | -10% | — |
| 5 | $HUM | HUMANA INC | $37.5M | 3.3% | NEW | 58.9 |
| 6 | $UNH | UNITEDHEALTH GROUP INC | $36.7M | 3.2% | +52% | 62.7 |
| 7 | $NBIX | NEUROCRINE BIOSCIENCES INC | $36.0M | 3.1% | -1% | 76.5 |
| 8 | $INBX | Inhibrx Biosciences, Inc. | $29.2M | 2.5% | +1% | 30 |
| 9 | $UTHR | UNITED THERAPEUTICS Corp | $27.1M | 2.4% | +26% | 71.3 |
| 10 | $RVMD | Revolution Medicines, Inc. | $26.8M | 2.3% | +2% | — |
| 11 |  $ICLR | ICON PLC | $23.7M | 2.1% | +137% | — |
| 12 |  $THC | TENET HEALTHCARE CORP | $23.7M | 2.1% | -68% | 66.2 |
| 13 |  $EW | Edwards Lifesciences Corp | $22.7M | 2.0% | -2% | 69.4 |
| 14 |  $WAT | WATERS CORP /DE/ | $22.4M | 1.9% | +50% | 60.4 |
| 15 |  $PEN | Penumbra Inc | $19.0M | 1.6% | -57% | 67.1 |
| 16 |  $BBIO | BridgeBio Pharma, Inc. | $18.9M | 1.6% | -2% | 36.9 |
| 17 |  $SYK | STRYKER CORP | $17.8M | 1.6% | +158% | 72.1 |
| 18 |  $MTD | METTLER TOLEDO INTERNATIONAL INC/ | $17.0M | 1.5% | NEW | 67.5 |
| 19 |  $INDV | Indivior Pharmaceuticals, Inc. | $16.5M | 1.4% | -30% | 58.5 |
| 20 |  $MRK | Merck & Co., Inc. | $16.3M | 1.4% | NEW | 59.9 |
| 21 |  $CYTK | CYTOKINETICS INC | $16.3M | 1.4% | NEW | 28.1 |
| 22 |  $LNTH | Lantheus Holdings, Inc. | $16.2M | 1.4% | NEW | 61.1 |
| 23 |  $CNC | CENTENE CORP | $16.0M | 1.4% | -6% | 58.2 |
| 24 |  $COO | COOPER COMPANIES, INC. | $15.8M | 1.4% | +30% | 57 |
| 25 |  $MDGL | MADRIGAL PHARMACEUTICALS, INC. | $15.7M | 1.4% | -14% | 40.7 |
| 26 |  $ACHC | Acadia Healthcare Company, Inc. | $15.5M | 1.4% | -10% | 36.7 |
| 27 |  $ORKA | Oruka Therapeutics, Inc. | $15.1M | 1.3% | -9% | — |
| 28 |  $OSCR | Oscar Health, Inc. | $14.8M | 1.3% | +4% | 83.1 |
| 29 |  $TMO | THERMO FISHER SCIENTIFIC INC. | $14.3M | 1.2% | +92% | 65.1 |
| 30 |  $CVS | CVS HEALTH Corp | $14.2M | 1.2% | NEW | 59.4 |
| 31 |  $MMSI | MERIT MEDICAL SYSTEMS INC | $13.7M | 1.2% | +21% | 64 |
| 32 |  $PRAX | Praxis Precision Medicines, Inc. | $12.9M | 1.1% | +9% | — |
| 33 |  $CLDX | Celldex Therapeutics, Inc. | $12.8M | 1.1% | +5% | 8.4 |
| 34 |  $NVO | NOVO NORDISK A S | $12.7M | 1.1% | +34% | — |
| 35 |  $ITGR | Integer Holdings Corp | $11.8M | 1.0% | -6% | 55.9 |
| 36 |  $DNTH | Dianthus Therapeutics, Inc. /DE/ | $11.8M | 1.0% | -30% | 22.6 |
| 37 |  $DFTX | Definium Therapeutics, Inc. | $11.7M | 1.0% | +21% | — |
| 38 |  $GILD | GILEAD SCIENCES, INC. | $11.5M | 1.0% | NEW | 57.4 |
| 39 |  $RYTM | RHYTHM PHARMACEUTICALS, INC. | $11.3M | 1.0% | -26% | 33.9 |
| 40 |  $HSIC | HENRY SCHEIN INC | $11.2M | 1.0% | -12% | 58.8 |
| 41 |  $ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $10.7M | 0.9% | +105% | 38.7 |
| 42 |  $TNGX | Tango Therapeutics, Inc. | $10.2M | 0.9% | -20% | 17.6 |
| 43 |  $TFX | TELEFLEX INC | $10.1M | 0.9% | NEW | 37.5 |
| 44 |  $VKTX | Viking Therapeutics, Inc. | $10.0M | 0.9% | -3% | — |
| 45 |  $BTSG | BrightSpring Health Services, Inc. | $9.9M | 0.9% | -24% | 63.3 |
| 46 |  $VERA | Vera Therapeutics, Inc. | $9.6M | 0.8% | +28% | — |
| 47 |  $ROIV | Roivant Sciences Ltd. | $9.5M | 0.8% | +29% | — |
| 48 |  $CGON | CG Oncology, Inc. | $9.1M | 0.8% | -23% | 27 |
| 49 |  $AMRX | Amneal Pharmaceuticals, Inc. | $8.3M | 0.7% | -48% | 58.5 |
| 50 |  $EPRX | EUPRAXIA PHARMACEUTICALS INC. | $8.0M | 0.7% | +124% | — |
| 51 |  $CORCALL | Cencora, Inc. | $8.0M | — | NEW | 61.1 |
| 52 |  $IRTC | iRhythm Holdings, Inc. | $7.8M | 0.7% | NEW | 54.8 |
| 53 |  $KOD | Kodiak Sciences Inc. | $7.5M | 0.7% | +69% | — |
| 54 |  $ABT | ABBOTT LABORATORIES | $7.5M | 0.7% | -41% | 65.5 |
| 55 |  $WST | WEST PHARMACEUTICAL SERVICES INC | $7.4M | 0.7% | NEW | 64.4 |
| 56 |  $TAK | TAKEDA PHARMACEUTICAL CO LTD | $7.1M | 0.6% | NEW | — |
| 57 |  $HNGE | Hinge Health, Inc. | $6.9M | 0.6% | NEW | 74.9 |
| 58 |  $ARQT | Arcutis Biotherapeutics, Inc. | $6.3M | 0.6% | NEW | 62.9 |
| 59 |  $IART | INTEGRA LIFESCIENCES HOLDINGS CORP | $6.3M | 0.5% | NEW | 48.2 |
| 60 |  $ILMN | ILLUMINA, INC. | $6.2M | 0.5% | +21% | 60.4 |
| 61 |  $MGTX | MeiraGTx Holdings plc | $6.2M | 0.5% | NEW | — |
| 62 |  $OCS | Oculis Holding AG | $6.0M | 0.5% | NEW | — |
| 63 |  $NTRA | Natera, Inc. | $6.0M | 0.5% | -63% | 53.5 |
| 64 |  $ABVX | Abivax S.A. | $5.8M | 0.5% | +62% | — |
| 65 | $CNCPUT | CENTENE CORP | $5.7M | — | NEW | 58.2 |
| 66 |  $GH | Guardant Health, Inc. | $5.5M | 0.5% | NEW | 39 |
| 67 |  $CELC | Celcuity Inc. | $5.5M | 0.5% | NEW | — |
| 68 |  $BLTE | BELITE BIO, INC | $5.4M | 0.5% | -41% | — |
| 69 |  $GPCR | Structure Therapeutics Inc. | $4.9M | 0.4% | -28% | — |
| 70 |  $RCUS | Arcus Biosciences, Inc. | $4.7M | 0.4% | NEW | 8.5 |
| 71 |  $CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | $4.3M | 0.4% | NEW | 43.8 |
| 72 |  $ELAN | Elanco Animal Health Inc | $4.2M | 0.4% | NEW | 48.7 |
| 73 |  $ARGX | ARGENX SE | $4.2M | 0.4% | -1% | — |
| 74 |  $BIO | BIO-RAD LABORATORIES, INC. | $4.1M | 0.4% | NEW | 48.9 |
| 75 |  $SYRE | Spyre Therapeutics, Inc. | $4.1M | 0.4% | NEW | — |
| 76 |  $MBX | MBX Biosciences, Inc. | $3.9M | 0.3% | -1% | — |
| 77 |  $MIRM | Mirum Pharmaceuticals, Inc. | $3.7M | 0.3% | NEW | 35 |
| 78 |  $CGEM | Cullinan Therapeutics, Inc. | $3.5M | 0.3% | -15% | — |
| 79 |  $CMPS | COMPASS Pathways plc | $3.5M | 0.3% | -82% | — |
| 80 |  $HCA | HCA Healthcare, Inc. | $3.2M | 0.3% | -38% | 68.9 |
| 81 |  $CAPR | CAPRICOR THERAPEUTICS, INC. | $2.9M | 0.3% | -1% | 13.6 |
| 82 |  $DNLI | Denali Therapeutics Inc. | $2.6M | 0.2% | NEW | — |
| 83 |  $SNDX | Syndax Pharmaceuticals Inc | $2.6M | 0.2% | -52% | 33.8 |
| 84 |  $AMLX | Amylyx Pharmaceuticals, Inc. | $2.6M | 0.2% | -1% | 8.7 |
| 85 |  $TARS | Tarsus Pharmaceuticals, Inc. | $2.6M | 0.2% | -49% | 55 |
| 86 |  $OM | Outset Medical, Inc. | $2.5M | 0.2% | -2% | 18.5 |
| 87 |  $OMDA | Omada Health, Inc. | $2.5M | 0.2% | NEW | 59.4 |
| 88 |  $ERAS | Erasca, Inc. | $2.5M | 0.2% | NEW | — |
| 89 | $COR | Cencora, Inc. | $2.1M | 0.2% | NEW | 61.1 |
| 90 |  $BCRX | BIOCRYST PHARMACEUTICALS INC | $2.1M | 0.2% | NEW | 53.2 |
| 91 |  $OMCL | OMNICELL, INC. | $2.0M | 0.2% | NEW | 51.9 |
| 92 |  $CVRX | CVRx, Inc. | $1.9M | 0.2% | NEW | 28.1 |
| 93 |  $HIMS | Hims & Hers Health, Inc. | $1.7M | 0.1% | NEW | 53.4 |
| 94 |  $MLYS | Mineralys Therapeutics, Inc. | $1.7M | 0.1% | -56% | — |
| 95 |  $TECX | Tectonic Therapeutic, Inc. | $1.6M | 0.1% | -1% | — |
| 96 |  $QURE | uniQure N.V. | $1.2M | 0.1% | -38% | — |
| 97 |  $RZLT | Rezolute, Inc. | $661,903 | 0.1% | -1% | — |
| 98 |  $CRBU | Caribou Biosciences, Inc. | $624,249 | 0.1% | -63% | 11.7 |
New Positions (34)
$HUM HUMANA INC$37.5M$MTD METTLER TOLEDO INTERNATIONAL INC/$17.0M$MRK Merck & Co., Inc.$16.3M$CYTK CYTOKINETICS INC$16.3M$LNTH Lantheus Holdings, Inc.$16.2M$CVS CVS HEALTH Corp$14.2M$GILD GILEAD SCIENCES, INC.$11.5M$TFX TELEFLEX INC$10.1M$CORCALL Cencora, Inc.$8.0M$IRTC iRhythm Holdings, Inc.$7.8M$WST WEST PHARMACEUTICAL SERVICES INC$7.4M$TAK TAKEDA PHARMACEUTICAL CO LTD$7.1M$HNGE Hinge Health, Inc.$6.9M$ARQT Arcutis Biotherapeutics, Inc.$6.3M$IART INTEGRA LIFESCIENCES HOLDINGS CORP$6.3MExited Positions (18)
$UTHRPUT UNITED THERAPEUTICS Corp
$GKOS GLAUKOS Corp
$CNTA Centessa Pharmaceuticals plc$UTHRCALL UNITED THERAPEUTICS Corp
$NEO NEOGENOMICS INC
$DXCM DEXCOM INC
$TERN Terns Pharmaceuticals, Inc.
$SLNO SOLENO THERAPEUTICS INC
$BLLN BillionToOne, Inc.
$CAH CARDINAL HEALTH INC
$ALHC Alignment Healthcare, Inc.
$PSNL Personalis, Inc.$ASNDCALL Ascendis Pharma A/SBrowse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for PFM Health Sciences, LP including:
Track PFM Health Sciences, LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for PFM Health Sciences, LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: PFM Health Sciences, LP
13F Pro is an AI hedge fund tracker and stock research platform. For PFM Health Sciences, LP (SEC CIK: 1442756), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in PFM Health Sciences, LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.